Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

IDF

- PMLiVE

AstraZeneca and CSPC Pharmaceuticals enter collaboration on weight management therapies

Almost three billion people globally are thought to be either overweight or obese

- PMLiVE

Novo Nordisk and Aspect Biosystems expand collaboration on diabetes research

The companies are working together on cellular medicines to boost, replace or repair biological functions

- PMLiVE

Eli Lilly’s Mounjaro shown to provide cardiovascular protection in type 2 diabetes patients

Approximately 38.4 million people in the US are affected by diabetes

- PMLiVE

Eli Lilly shares promising phase 3 results for once-weekly insulin candidate efsitora alfa

The company is planning to submit regulatory applications for the candidate by the end of the year

regeneron headquarters

Regeneron gains rights to Hansoh’s GLP-1/GIP receptor agonist in deal worth $2bn

The candidate is being evaluated in a phase 3 obesity trial and phase 2b diabetes study

- PMLiVE

Novo Nordisk gains rights to United Laboratories’ triple receptor agonist in deal worth $2bn

UBT251 is in early-stage clinical development for type 2 diabetes, obesity and other diseases

- PMLiVE

Novo shares phase 3 results for obesity candidate CagriSema in diabetes patients

The company is expecting to file for the first regulatory approval of the drug next year

- PMLiVE

Novo Nordisk’s Ozempic granted FDA approval in chronic kidney disease

The progressive condition affects approximately 40% of type 2 diabetes patients

- PMLiVE

Novo shares promising results for high-dose semaglutide in late-stage obesity study

The experimental dose is also being evaluated in adults with obesity and type 2 diabetes

- PMLiVE

Novo Nordisk and Valo Health expand alliance for cardiometabolic diseases

The partners are aiming to develop new drugs for type 2 diabetes, obesity and cardiovascular disease

- PMLiVE

Eli Lilly announces $3bn expansion to US injectables manufacturing facility

The investment will help Lilly meeting the growing demand for its diabetes and obesity medicines

- PMLiVE

Sanofi unveils plans to build €1bn insulin production base in China

The site will focus on serving the insulin medication needs of local diabetic patients

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links